The Society for Immunotherapy of Cancer (SITC) published it's first clinical practice guideline (CPG) on immunotherapy for the treatment of Head and Neck Squamous Cell Carcinoma in the Journal for ImmunoTherapy of Cancer on July 15, 2019.SITC's Cancer Immunotherapy Guidelines program is a collection of CPGs developed by multi-disciplinary panels of experts who draw from their own practical experience as well as evidence in the published literature and clinical trial data to develop evidence- and consensus-based recommendations. SITC uses as a model the Institute of Medicine's 2011 "Standards for Developing Trustworthy Clinical Practice Guidelines" to ensure the recommendations are unbiased, transparent and balanced will aid oncologists in effective clinical decision-making concerning patient selection, toxicity management, response evaluation, and the sequencing or combination of therapies, among other topics.
The Head and Neck Squamous Cell Carcinoma CPG was developed collaboratively through the efforts of an expert panel that convened to discuss the current therapeutic landscape. This CPG provides recommendations for FDA-approved immunotherapies for head and neck squamous cell carcinoma, as well as discussion of promising emerging treatment modalities and patient quality of life issues.
Learn more about immunotherapy treatment standards for squamous cell carcinoma of the head and neck (HNSCC) and hear about the Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC) in this free one-hour webinar. SITC hosted this session on Wednesday, July 24, 2019 featuring members of the Cancer Immunotherapy Guideline – Head and Neck Expert Panel.
VIEW ON-DEMAND WEBINAR
R. Bryan Bell, MD, DDS, FACS — Earle A. Chiles Research Institute, Providence Cancer Institute
Barbara A. Burtness, MD — Yale University School of Medicine
Maura L. Gillison, MD, PhD — The University of Texas MD Anderson Cancer Center
Kevin Harrington, PhD, FRCP, FRCR — The Institute of Cancer Research
Quynh-Thu Le, MD, FACR, FASTRO — Stanford University
Nancy Y. Lee, MD — Memorial Sloan Kettering Cancer Center
Rom Leidner, MD — Earle A. Chiles Research Institute, Providence Cancer Institute
Rebecca L. Lewis, CRNP — UPMC Hillman Cancer Center
Lisa Licitra, MD — Fondazione IRCCS Instituto Nazionale dei Tumori
Hisham Mehanna, PhD — Institute of Head and Neck Studies and Education
Loren K. Mell, MD — Dept. of Radiation Medicine and Applied Sciences, UC-San Diego
Adam Raben, MD — Christiana Care Health System
Andrew G. Sikora, MD, PhD — Baylor College of Medicine
Ravindra Uppaluri, MD, PhD — Dana-Farber Cancer Institute
Fernanda Whitworth — Co-founder of The Immunotherapy Foundation
Dan P. Zandberg, MD — UPMC Hillman Cancer Center
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com